Unlike ameloblastoma, BRAF mutations only occur in ~1.8% of HNSCC, and the clinical responsiveness of BRAF-mutated HNSCC patients to BRAF inhibition remains under-explored. The gene discussed is BRAF; the disease is head and neck squamous cell carcinoma.